JACOBIO-B (01167) announced that to further advance the group's global strategic layout and enhance cross-regional operational efficiency, the board of directors has approved the establishment of a "Co-Chief Executive Officer" (Co-CEO) system. Dr. Andrea Wang-Gillam (Wang Yi), currently serving as Chief Medical Officer (CMO), was appointed as the company's Co-CEO on November 12, 2025.

Dr. Wang Yi has extensive experience in the international pharmaceutical market, with deep expertise in clinical trial regulations, regulatory environments, healthcare systems, and commercialization logic in Europe and the U.S. With over 20 years of experience as an oncologist in the U.S., she has led multiple clinical trials for anti-cancer drugs and is internationally recognized as a clinical expert in gastrointestinal oncology. Additionally, as an associate professor at Washington University in St. Louis, she has long been engaged in foundational oncology research, demonstrating profound insights into global clinical strategies and research directions for anti-cancer drugs.

This adjustment represents a key step in the group's globalization strategy, aiming to establish a synergistic model of "global strategic coordination + regional execution" to create greater value for shareholders.